![]() |
|
|
Vol. 30, Issue 5, 488-493, May 2002
Biomedical Research Institute (T.S.) and Laboratory of Biomedical Pharmacology and Toxicology (M.H., T.S.), Chiba University, Chiba, Japan; Department of Pharmacology, University of California at San Diego (P.T.), La Jolla, California; Department of Biochemistry and Molecular Biology, Indiana University School of Medicine (W.F.B., S.P.S.), Indianapolis, Indiana; Department of Pharmacology, University of Michigan School of Medicine (B.N.L.D.), Ann Arbor, Michigan
| |
Abstract |
|---|
, -Hydrolase-Fold Proteins: A...
|
|---|
This article reports on a symposium sponsored by the American Society for Pharmacology and Experimental Therapeutics and held at the April 2001 Experimental Biology meeting. Current developments in molecular-based studies into the structure and function of cholinesterases, carboxylesterases, and paraoxonases are described. This article covers mechanisms of regulation of gene expression of the various esterases by developmental factors and xenobiotics, as well as the interplay between physiological and chemical regulation of enzyme activity.
| |
Introduction |
|---|
, -Hydrolase-Fold Proteins: A...
|
|---|
This article summarizes four presentations (by P.T., W.F.B., M.H., and B.N.L.D.) at a symposium chaired by T.S. and sponsored by the American Society for Pharmacology and Experimental Therapeutics at the April 2001 Experimental Biology meeting in Orlando, FL. These presentations highlight the importance of structure in delineating overall function, substrate specificity, and localization of the esterase enzymes. Structural considerations emerge from the genes encoding the family of enzymes. Sequence homology typically yields insights into the evolutionary relationships between the members and the conserved and divergent areas of sequence. Diversity in the structure and ultimately function and cellular localization of the gene product is achieved through gene doubling and divergence, alternative mRNA processing, and post-translational modifications.
The cholinesterases and carboxylesterases belong to a protein
superfamily termed the
,
-hydrolase-fold family (Cygler et al.,
1993
) in which members may have highly specialized functions, as is the
case for acetylcholinesterase and juvenile hormone esterase. These
members show a high degree of selectivity for a neurotransmitter or a
hormone, respectively. Other members of the family, such as
butyrylcholinesterase or the wide variety of carboxylesterases found in
tissues and plasma, show greater promiscuity in substrates for which
they catalyze. Hence, they serve a protective and clearing function for
foreign substances encountered through the diet or other routes of
exposure. This family of enzymes also shows great differences in the
cells in which they are expressed; some are found in multiple cell
types, whereas others show highly selective expression. Finally, within
the cell itself, we observe distinctive localizations; some of the
enzymes are destined for export into the plasma, others associate with
the cell membrane with its catalytic function directed extracellularly.
Others may be retained within subcellular organelles, such as the
endoplasmic reticulum, whereas still others are found in the cytoplasm.
This article details the signal sequences and splice options that
govern cellular localization.
Although we know less about the structures of the paraoxonases, it is clear that they are not serine or cysteine esterases. Rather, they belong to a discrete family of esterases, most likely ones in which a divalent metal is required for catalysis. Considerable progress has been made recently in their purification and structural elucidation. Importantly, inroads also have been made in detecting the natural substrates for the paraoxonases, and as alluded to in this article, lactones emerge as a prime candidate across several species.
Expression profiles of genes encoding esterases are highly regulated during development by nutritional status, hormonal factors, and xenobiotics. Although the consequences of regulation of esterases by drugs and chemicals have been intensively studied, relatively little is known about the mechanisms by which esterases are regulated by physiological factors. This regulation has several potential consequences for pharmacological and toxicological actions of drugs and chemicals in humans and animals in different developmental stages and nutritional states.
| |
, -Hydrolase-Fold Proteins: A Unique Superfamily of Proteins
with a Diversity of Catalytic and Noncatalytic Functions (P.T.) |
|---|
, -Hydrolase-Fold Proteins: A...
|
|---|
Proteins conforming to the structure of the
,
-hydrolase-fold
family (Cygler et al., 1993
) have emerged as a growing superfamily of
proteins with a wide range of functional properties. That
cholinesterase was to define a unique family of proteins became evident
16 years ago (Schumacher et al., 1986
) when it was noted that the
sequence of acetylcholinesterase bore no resemblance to sequences of
other known serine hydrolases but rather showed sequence homology to thyroglobulin, a protein whose cDNA was cloned at nearly the same time
(Swillens et al., 1986
).
The idea that an enzyme designed to hydrolyze rapidly a
neurotransmitter would show identity with the protein thyroglobulin, which functions as a substrate for tyrosine iodination and conjugation ultimately leading to thyroxin formation, made little sense at the
time. As this protein superfamily grew, three global functions could be
ascribed to its members: 1) hydrolytic catalysis of a wide variety of
substrates; 2) heterologous cellular recognition as seen for the
tactins and between neuroligin and neurexin; and 3) a matrix for
post-translational modifications of amino acid residues as found for
thyroglobulin. At present, the database for this family contains over
450 orthologous or homologous members with 44 distinctive functions
(http://www.ensam.enra.fr/cgi-bin/ace/index). Figure
1 shows the major structural similarities
of several distinctive proteins of the
,
-hydrolase-fold family.
It is also apparent that the family has a variety of means for
attaching the catalytic or functional domain to the membrane. Although
most activities involve catalysis of hydrolysis or hydrolytically
coupled reactions, annotations of ongoing databases are probably not
only going to increase the number of members of this superfamily but
also identify several new members, perhaps with unique noncatalytic
functions.
|
Dual functions in a single protein, such as hydrolytic catalysis and forming heterologous cell adhesive contacts for certain family members, remain an attractive but unproven possibility. Moreover, interactions between heterologous-neighboring proteins for members of this family may offer a means of delimiting catalysis to the context of associated proteins within the cell or subcellular organelle.
Since neuroligin is a mammalian protein and possesses the greatest
sequence identity with the cholinesterases (Ichtchenko et al., 1995
),
our initial studies have characterized neuroligin's interactions with
its presynaptic partner neurexin. The extracellular portion of
neuroligin, a region homologous to other
,
-hydrolase-fold proteins, contains the recognition domain(s) for its
Ca2+-dependent interactions with neurexin
(Tsigelny et al., 2000
). This extracellular domain of the protein can
be expressed as a soluble entity, and its interaction with neurexin can
be studied by surface plasmon resonance. Similar to the behavior of the
developmental protein notch (Molaney et al., 2000
), glycosylation
processing at certain positions on neuroligin inhibits its associations
with neurexin.
Basis for Catalytic Diversity of the
,
-Hydrolase-Fold
Proteins.
The
,
-hydrolase-fold proteins show great diversity not only in
their substrate recognition but also in catalytic parameters. For
example, acetylcholinesterase is one of the most efficient enzymes
known with rates of catalysis occurring at or near the diffusion
limitation. By contrast, juvenile hormone esterase shows a
kcat that is 4 orders of magnitude
slower but with a higher affinity (lower
Km) for the substrate (Thomas et al.,
1999
). The juvenile hormone esterases have
Km values ranging between 1 and 102 nM, whereas the Km value for
acetylcholinesterase is about 50 µM. Since juvenile hormone
esterase substrates contain an extended hydrophobic acyl group and
small alcohol moiety (methanol) and acetylcholinesterase requires a
small acyl group for efficient catalysis, it is probably the substrate
orientations in the active center of two enzymes that differ with
respect to the entry portal and the position of the catalytic serine in
the active center.
-loop extending
between the disulfide-linked cysteines residues 69 and 96 is in a homologous position with the activation flap on the fungal lipase (Cygler et al., 1993
-loop may be
critical to the catalytic cycle of acylation and deacylation, and the
binding of ligands seems to distort the loop structure, as revealed by
the fluorescence characteristics of the acrylodan conjugated at
particular cysteines in the molecule (Shi et al., 2001
,
-hydrolase-fold proteins arises from
alternative mRNA splicing. This region governs the cellular disposition
of the acetylcholinesterases but does not affect their catalytic
properties. The most prevalent splice option encodes for a carboxyl
terminus containing a disulfide for linkage to other catalytic subunits
or to either a collagen-like or lipid-linked structural subunit. Other
splice options give rise to a glycophospholipid-linked enzyme or a
soluble monomeric species. Tissue-specific splicing has been examined
in several systems.
| |
Identification and Substrate Specificity of Human Carboxylesterases, hCE-1, and hCE-2 (S.P.S. and W.F.B.) |
|---|
, -Hydrolase-Fold Proteins: A...
|
|---|
Mammalian liver carboxylesterases belong to a family of proteins
encoded by multiple genes. The isoenzymes were initially classified by
their substrate specificity and pI. However, this classification is now
ambiguous because of overlapping substrate specificities and imprecise
because the carboxylesterases as glycoproteins exhibit multiple bands
with different pI values upon electrophoresis. Satoh and Hosokawa
(1998)
recommended an improved classification based on sequence
alignments of the encoding genes.
The isoenzymes were classified into four main carboxylesterase (CES1) groups and several subgroups. In general, carboxylesterases exhibit about 80% sequence identity within a CES group. The two major human liver isoenzymes hCE-1 (GI: 119576) and hCE-2 (GI: 4504565) belong to classes CES1 and CES2, respectively. In this article, we summarize the tissue-specific expression and substrate specificity of the hCE-1 and hCE-2 isoenzymes.
Tissue-specific expression of human carboxylesterases hCE-1 and hCE-2
was examined by Northern blots of adult tissues. As shown in Fig.
2, a single band of approximately 2.1 kb
was seen for hCE-1 (Riddles et al., 1991
) and three bands of
approximately 2, 3, and 4.2 kb were seen with hCE-2 (Schwer et al.,
1997
). Both mRNAs are highly expressed in liver. For hCE-1, the
intensities of the 2.1-kb band was liver
heart > stomach > testis = kidney = spleen > colon > other
tissues (Fig. 2). For hCE-2, the abundance of the 2-kb message in adult
tissues was liver > colon > small intestine > heart,
and 3-kb message was liver > small intestine > colon > heart (Fig. 2). A 4.2-kb message was detected in brain, testis, and
kidney only. hCE-2 expression was essentially absent in other tissues.
|
It is not known why the relative intensity of the 2- and 3-kb bands for hCE-2 vary in different tissues, but it could be due to alternate splicing, use of different start sites, or expression of different but highly homologous genes. The implications for drug metabolism are that both hCE-1 and hCE-2 are important for systemic clearance of esters from blood through the liver. hCE-1 seems more important for clearance through the kidney, whereas hCE-2 is important for clearance of orally administered drugs through the small intestine and colon.
A rapid spectrophotometric assay examining the hydrolysis of
4-methylumbelliferyl acetate to 4-methylumbelliferone
(
max, 350 nm) was routinely used during
purification and characterization of hCE-1 and hCE-2 (Brzezinski et
al., 1994
; Humerickhouse et al., 1997
; Pindel et al., 1997
). The
catalytic efficiency of 4-methylumbelliferyl acetate is about 1000 times that of the drug esters investigated in this study (Fig.
3).
|
The catalytic efficiencies of hCE-1 and hCE-2 for several
pharmaceuticals were examined (Fig. 3). For drugs of abuse, heroin shows the highest rates of catalysis by both enzymes. hCE-1, but not
hCE-2, hydrolyzed the methyl ester of cocaine and the ethyl esters of
meperidine and delapril. In contrast to the specificity of hCE-1 for
the methyl ester of cocaine, only hCE-2 hydrolyzed the benzoyl ester of
cocaine. The benzoyl group of cocaine is also hydrolyzed by serum
butyrylcholinesterase (Mattes et al., 1996
; Lynch et al., 1997
). For
the remaining substrates that could be hydrolyzed by both enzymes,
hCE-2 exhibited higher catalytic efficiency than hCE-1 for heroin;
enzymatic conversion of 6-acetylmorphine to morphine was not known
before the isolation and characterization of hCE-2 (Kamendulis et al.,
1996
). Takai et al. (1997)
also reported that hCE-2 (a form with pI
4.5) had higher activity with irinotecan (CPT-11) than hCE-1 (form with
pI 5.3).
Analysis of substrate structure versus catalytic efficiency for
the ester or carbamate substrates reveals that the two
carboxylesterases recognize different structural features of the
substrate. The catalytic mechanism for carboxylesterases involves
formation of an acyl-enzyme intermediate on an active site serine. If
we divide the enzyme active site into "alcohol" and "acyl or
acid" recognition subsites, we find the following relationships for
hCE-1 and hCE-2 reactively. For those substrates in which
hCE-1-catalytic efficiency is greater than hCE-2, such as cocaine
(methyl ester), meperidine (Zhang et al., 1999
), and delapril (Fig. 3),
the alcohol site recognizes the smaller groups (e.g., methanol and
ethanol), and the acyl (acid) site recognizes the larger multiring
substitutes of these drugs. For those substrates in which hCE-2
catalytic efficiency is greater than hCE-1, such as
4-methylumbelliferyl acetate, cocaine (benzoyl ester), heroin, and
6-acetylmorphine (Fig. 3), the alcohol site recognizes the bulky
multiring groups, and the acyl (acid) site recognizes the relatively
smaller carboxylate groups. CPT-11 follows a similar relationship in
which hCE-2 hydrolyzes the bulky multiring alcohol SN-38 group better
than hCE-1 even though the bulky piperidine/bicarbonate products would
presumably occupy the acyl (acid) site of hCE-2.
Takai et al. (1997)
compared hydrolysis of many drugs catalyzed by
hCE-1 (pI 5.3) and hCE-2 (pI 4.5). Several angiotensin-converting enzyme (ACE) inhibitors, such as benazepril, cilazapril, quinapril, temocapril, delapril, and imidapril were studied. All of these drugs
are ethyl esters with large acyl group (Fig. 3), and they are better
substrates for hCE-1. Delapril and imidapril were hydrolyzed only by
hCE-1 and not hCE-2. In contrast, Takai et al. (1997)
reported that the
local anesthetic drug procaine and the anticholinergic drug oxybutynin
with large alcohol substitutes are substrates for hCE-2 but not hCE-1.
Enzyme preference is less selective for substrates, such as camostat
and dilazep, that have both large alcohol and acyl substituents (Takai
et al., 1997
).
In general, the alcohol binding site in hCE-1 accepts small groups
relative to the acyl (acid) site (Fig. 3). This relationship is also
seen with the increasing Ki to
inhibitors and for longer chain alkylesters of cocaine for hCE-1
[e.g., benzoylecgonine methyl ester (cocaine) < benzoylecgonine
ethyl ester < benzoylecgonine propyl ester (Brzezinski et al.,
1997
)]. As the size of the group in the alcohol binding site
increases, hydrolase activity of hCE can be completely lost (e.g.,
procaine and oxybutynin) (Takai et al., 1997
).
In contrast to hCE-1, hCE-2 can efficiently hydrolyze compounds with large alcohol groups (Fig. 3). However, there is a limit to the size of the group that can be accommodated in the acyl binding site. For example, meperidine and delapril are not substrates for hCE-2. We conclude that although these two human carboxylesterases exhibit broad substrate specificity for ester, carbamate, or amide hydrolysis, they do exhibit distinct catalytic efficiencies that correlate with the relative size of the substrate substituents versus that of the enzyme active sites. Knowledge of these substrate structure-activity relationships and the tissue distribution of carboxylesterase isoenzymes is critical to predicting the metabolism and pharmacokinetics of drug esters in humans.
| |
Molecular Cloning and Expression of Liver, Intestine, and Brain Carboxylesterase Isozymes: The Role in Metabolic Activation of Drugs (M.H. and T.S.) |
|---|
, -Hydrolase-Fold Proteins: A...
|
|---|
Mammalian carboxylesterases (EC 3.1.1.1) compose a multigene
family, the gene products of which are localized in the endoplasmic reticulum of many tissues (Hosokawa et al., 1987
, 1990
, 1995
, 2001
;
Maki et al., 1991
; Satoh et al., 1994
; Yamada et al., 1994
; Satoh and
Hosokawa, 1995
, 1998
; Takayama et al., 1998
; Mori et al., 1999
). These
enzymes efficiently catalyze the hydrolysis of a variety of drugs or
prodrugs containing ester- and amide-bonds to the respective free acids
and alcohol. Since ester derivatives of therapeutic agents have been in
use as prodrugs, carboxylesterases are major determinants of the
pharmacokinetic behavior of most prodrugs, and the activity can be
influenced by direct interactions with a variety of compounds, either
directly or by enzyme regulation (Hosokawa et al., 1993
, 1994
,
1998
).
The mammalian carboxylesterases are localized in the endoplasmic
reticulum of many tissues. Among various tissues of animals, the
highest substrate hydrolase activity is typically found in the liver
(Hosokawa et al., 2001
), but activities can be found in several other
tissues, such as testis, kidney, and plasma (Morgan et al., 1994
).
Since a significant number of drugs are metabolized by
carboxylesterases, altering activities of these enzymes expressed in
each tissue has important clinical implications. However, little is
known about the differences in structure and hydrolytic capabilities of
carboxylesterase isozymes expressed in tissues of humans. Structural characterizations of carboxylesterase isozymes, their expression in
various tissues, and their substrate specificities provide important
insights into the molecular basis for their functional differences in humans.
Recombinant DNA and expression techniques have been introduced to the
field of carboxylesterases as a means to clarify the substrate
specificity of each isozyme, elucidate the catalytic mechanism of
carboxylesterases, and delineate the role of carboxylesterases in the
endoplasmic reticulum. Several proteins of endoplasmic reticulum lumen
have the common carboxy-terminal recognition sequence KDEL-COOH, a
structural motif essential for retention of the protein in the luminal
site of the endoplasmic reticulum (Satoh and Hosokawa, 1998
). Proteins
with this carboxy-terminal sequence bind the KDEL receptor and
associate with the endoplasmic membrane. Our group showed that the
endoplasmic reticulum retention motif of carboxylesterase is HXEL-COOH
(Satoh and Hosokawa, 1995
). The recognition sequence dictates that
proteins are primarily found on the luminal side of the endoplasmic
reticulum. The three amino acid residues of the catalytic triad (Ser,
Glu, and His) and four cysteines that may be involved in specific
disulfide bonds are similarly positioned in each carboxylesterase, and
some N-linked glycosylation sites are also conserved. It is
interesting that human liver and brain carboxylesterase (HU1 and hBr1)
have a free cysteine residue that is not involved in a disulfide bond.
Recently, Satoh and Hosokawa (1998)
proposed a novel classification and
nomenclature of carboxylesterase isozymes. Considering the high-residue
identity and similarity of the characteristics, they proposed that
carboxylesterase isozymes be classified into four families, CES1, CES2,
CES3, and CES4, a classification based on phylogenetic analysis.
According to the classification, human liver HU1, and human brain hBr1,
hBr2, and hBr3 belong to the CES1 family. Human liver HU3 and intestine HSICE are classified into the CES2 family.
Ester and amide derivatives of therapeutically active agents have been
in use as prodrugs for many years to improve solubility, absorption,
and bioavailability, and to extend duration of action of the drug,
camptothecin derivatives, such as topotecan and CPT-11, are used as
antineoplastic agents and possess a novel mechanism of action involving
inhibition of DNA topoisomerase I. CPT-11, a carbamate derivative of
10-hydroxy-7-ethylcamptothecin, can be classified as a prodrug because
we and others found conversion of CPT-11 to its active metabolite
10-hydroxy derivatives by liver carboxylesterase in various mammals and
humans (Satoh and Hosokawa, 1993
; Satoh et al., 1994
; Takayama et al.,
1998
). The Km value of human intestine
HSICE is lower than liver HU1, and the
Vmax value of HSICE is higher than
HU1. Therefore, human intestine carboxylesterase has a much higher
capability of CPT-11 hydrolase activity than human liver
carboxylesterase. Temocapril is a prodrug type of the ACE inhibitor
that is rapidly hydrolyzed by carboxylesterase at its 2'-ethyl ester
group and converted into the pharmacologically active diacid metabolite
temocaprilat, a potent inhibitor of ACE. The comparison
of the temocapril hydrolase activity in human liver and brain
carboxylesterase was expressed in V79 cells. Human brain carboxylesterase hBr2 was found to have the highest specific activity toward temocapril. However, human intestinal carboxylesterase poorly
catalyzes the hydrolysis of temocapril. These results suggest that the
therapeutic prodrug was metabolically activated by human carboxylesterases isozymes, although the capability of metabolic activation was different for each isozyme.
In conclusion, recent studies demonstrate that liver, small intestine, and brain carboxylesterase isozymes in humans are intimately involved in metabolic activation of therapeutic prodrugs. The multiplicity of carboxylesterase structures enable this family of enzymes to hydrolyze a diverse range of esters.
| |
Evolution and Enzymatic Properties of Mammalian Paraoxonases (B.N.L.D.) |
|---|
, -Hydrolase-Fold Proteins: A...
|
|---|
Augustinsson (1968)
proposed that arylesterases arose as an
offshoot from the carboxylesterase but differ in having cysteine rather
than serine as the key component of their active centers. Although this
hypothesis remained unchanged for many years, we now know that the
mammalian paraoxonase/arylesterase (PON1) requires calcium and does not
need a free cysteine residue for paraoxonase activity. Three such
esterases (PON1, PON2, and PON3) have been named in the order of their
discovery. The corresponding three genes are closely aligned on
chromosome 7 in humans and on chromosome 6 in mice. Since there is no
structural similarity in the amino acid sequences of the PONs with
sequences of the cholinesterases or the carboxylesterases, it is now
quite evident that they are not related, and ancestral relatives of the
PONs must be found elsewhere.
A recent, very relevant report showed that a lactonase of the fungus
Fusarium oxysporium (Kobayashi et al., 1999
) has appreciable structural homology with human serum PON1. Furthermore, these two
enzymes share a number of substrates, such as dihydrocoumarin and
homogentisic acid lactone. Interestingly, the fungal lactonase does not
catalyze the hydrolysis of paraoxon.
Our laboratory has recently characterized the lactonase activity of
purified human PON1 (Billecke et al., 2000
) and found it to hydrolyze a
large number of both aromatic and aliphatic lactones. Its substrates
also include a number of drugs, such as several statin lactones
(lovastatin and simvastatin) and the diuretic agent spironolactone. The
rates of hydrolysis are different for some of these substrates with the
two purified human PON1 Q and R isozymes and show stereospecificity for
some of the lactone enantiomers. Since lactones are commonly found in
plants, natural flavoring agents, and many food products, we may find
that PON1 lactonase activity represents the common theme of this family of enzymes. Protection against dietary and environmental lactones could
be the selective forces that have been responsible for maintaining the
balanced polymorphisms in the PON enzymes in mammals.
Support for the key role of the lactonase activity comes from the
recent findings in our laboratory that neither human PON2 nor PON3 have
any paraoxonase activity. They have very little if any arylesterase
activity, but they share the lactonase activity of PON1 (D. Draganov,
unpublished results). Rabbit serum contains PON3 in its HDL fraction,
and it has a very high statinase activity (Draganov et al.,
2000
). A recent report identifies human serum PON3 as a minor component
of the HDL fraction, but its enzymatic activity still must be examined
(Reddy et al., 2001
).
On the basis of the structural homology and predicted evolutionary
distance between them, it seems that PON2 is the oldest member of the
family, PON3 arose from it, and finally PON1 appears. All three PONs
have nine similar exons and a high degree of identity in their
structural characteristics, such as number and location of the cysteine
residues. Based on their respective cDNA structures and the deduced
amino acid sequences, there is over 80% identity in amino acid
residues in human, mouse, and rabbit PON1s and at least 60% identity
between the PONs 1,2, and 3 of each of these species (Primo-Parmo et
al., 1996
). Polymorphic variants are common in at least the human and
rabbit PONs. A reasonable conclusion from these observations is that
this family of enzymes probably has some important physiological role,
which is protected by the redundancy and polymorphic forms of the
enzymes produced.
An important clue to a physiological function is provided by the
studies of mice lacking PON1 that were produced by Shih et al. (1998)
.
The knockout mice developed atherosclerosis when fed an atherogenic
diet, and their HDL fraction lacking PON1 was not protective against
oxidative damage produced by low-density lipoprotein, as was found for
the HDL fraction from wild-type mice. Purified PON1 showed the expected
protection against oxidative damage from low-density lipoprotein, and
purified rabbit serum PON3 was even more protective than rabbit
purified PON1 (Draganov et al., 2000
). Although lactonase activity with
model compounds and protection against oxidative damage seem to be
parallel activities, it is not clear how directly they are related.
Perhaps protection involves the hydrolysis of some potentially toxic
endogenous lactone that would produce oxidative damage if not
hydrolyzed. Such questions will be answered by future research. A
useful recent review on the relationship between PON1 and
atherosclerosis has been published by Durrington et al. (2001)
.
| |
Footnotes |
|---|
Received November 28, 2001; accepted January 22, 2002.
Address correspondence to: Palmer Taylor, Department of Pharmacology, University of California at San Diego, 9500 Gilman Drive, Basic Science Bldg., La Jolla, CA 92093-0636. E-mail: pwtaylor{at}ucsd.edu
| |
Abbreviations |
|---|
Abbreviations used are: CES, carboxylesterase; kb, kilobase; CPT-11, irinotecan; SN-38, 7-ethyl-10-hydroxycamptothecin; ACE, angiotensin-converting enzyme; PON, paraoxonase; HDL, high-density lipoprotein.
| |
References |
|---|
, -Hydrolase-Fold Proteins: A...
|
|---|
-carbonitrile.
Biochem Pharmacol
45:
2317-2322[CrossRef][Medline].This article has been cited by other articles:
![]() |
E. Sjodin, H. Fritsch, U. G. Eriksson, U. Logren, A. Nordgren, P. Forsell, L. Knutson, and H. Lennernas Intestinal and Hepatobiliary Transport of Ximelagatran and Its Metabolites in Pigs Drug Metab. Dispos., August 1, 2008; 36(8): 1519 - 1528. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. T. Williams, K. O. Jones, G. D. Ponsler, S. M. Lowery, E. J. Perkins, S. A. Wrighton, K. J. Ruterbories, M. Kazui, and N. A. Farid The Biotransformation of Prasugrel, a New Thienopyridine Prodrug, by the Human Carboxylesterases 1 and 2 Drug Metab. Dispos., July 1, 2008; 36(7): 1227 - 1232. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ose, H. Kusuhara, K. Yamatsugu, M. Kanai, M. Shibasaki, T. Fujita, A. Yamamoto, and Y. Sugiyama P-glycoprotein Restricts the Penetration of Oseltamivir Across the Blood-Brain Barrier Drug Metab. Dispos., February 1, 2008; 36(2): 427 - 434. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Schiel, S.-l. Green, W. I. Davis, P. C. Sanghani, W. F. Bosron, and S. P. Sanghani Expression and Characterization of a Human Carboxylesterase 2 Splice Variant J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 94 - 101. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-R. Kim, K. Sai, T. Tanaka-Kagawa, H. Jinno, S. Ozawa, N. Kaniwa, Y. Saito, A. Akasawa, K. Matsumoto, H. Saito, et al. Haplotypes and a Novel Defective Allele of CES2 Found in a Japanese Population Drug Metab. Dispos., October 1, 2007; 35(10): 1865 - 1872. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Imai, M. Taketani, M. Shii, M. Hosokawa, and K. Chiba Substrate Specificity of Carboxylesterase Isozymes and Their Contribution to Hydrolase Activity in Human Liver and Small Intestine Drug Metab. Dispos., October 1, 2006; 34(10): 1734 - 1741. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Godin, E. J. Scollon, M. F. Hughes, P. M. Potter, M. J. DeVito, and M. K. Ross Species Differences in the in Vitro Metabolism of Deltamethrin and Esfenvalerate: Differential Oxidative and Hydrolytic Metabolism by Humans and Rats Drug Metab. Dispos., October 1, 2006; 34(10): 1764 - 1771. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Polsky-Fisher, H. Cao, P. Lu, and C. R. Gibson EFFECT OF CYTOCHROMES P450 CHEMICAL INHIBITORS AND MONOCLONAL ANTIBODIES ON HUMAN LIVER MICROSOMAL ESTERASE ACTIVITY Drug Metab. Dispos., August 1, 2006; 34(8): 1361 - 1366. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Zhang, S. S. Dehal, T. Ho, J. Johnson, C. Chandler, A. P. Blanchard, R. J. Clark Jr., C. L. Crespi, D. M. Stresser, and J. Wong HUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81 Drug Metab. Dispos., May 1, 2006; 34(5): 734 - 737. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Nakamura, Y. Kawakita, A. Yasuhara, Y. Fukasawa, K. Yoshida, K. Sakagami, and A. Nakazato IN VITRO AND IN VIVO EVALUATION OF THE METABOLISM AND BIOAVAILABILITY OF ESTER PRODRUGS OF MGS0039 (3-(3,4-DICHLOROBENZYLOXY)-2-AMINO-6-FLUOROBICYCLO[3.1.0]HEXANE-2,6-DICARBOXYLIC ACID), A POTENT METABOTROPIC GLUTAMATE RECEPTOR ANTAGONIST Drug Metab. Dispos., March 1, 2006; 34(3): 369 - 374. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. P. Landowski, P. L. Lorenzi, X. Song, and G. L. Amidon Nucleoside Ester Prodrug Substrate Specificity of Liver Carboxylesterase J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 572 - 580. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kubo, S.-R. Kim, K. Sai, Y. Saito, T. Nakajima, K. Matsumoto, H. Saito, K. Shirao, N. Yamamoto, H. Minami, et al. FUNCTIONAL CHARACTERIZATION OF THREE NATURALLY OCCURRING SINGLE NUCLEOTIDE POLYMORPHISMS IN THE CES2 GENE ENCODING CARBOXYLESTERASE 2 (HCE-2) Drug Metab. Dispos., October 1, 2005; 33(10): 1482 - 1487. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Imai, M. Imoto, H. Sakamoto, and M. Hashimoto IDENTIFICATION OF ESTERASES EXPRESSED IN CACO-2 CELLS AND EFFECTS OF THEIR HYDROLYZING ACTIVITY IN PREDICTING HUMAN INTESTINAL ABSORPTION Drug Metab. Dispos., August 1, 2005; 33(8): 1185 - 1190. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Fujikawa, T. Satoh, A. Suganuma, S. Suzuki, Y. Niikura, S. Yui, and Y. Yamaura Extremely sensitive biomarker of acute organophosphorus insecticide exposure Human and Experimental Toxicology, June 1, 2005; 24(6): 333 - 336. [Abstract] [PDF] |
||||
![]() |
S. K. Quinney, S. P. Sanghani, W. I. Davis, T. D. Hurley, Z. Sun, D. J. Murry, and W. F. Bosron Hydrolysis of Capecitabine to 5'-Deoxy-5-fluorocytidine by Human Carboxylesterases and Inhibition by Loperamide J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1011 - 1016. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. P. Landowski, B. S. Vig, X. Song, and G. L. Amidon Targeted delivery to PEPT1-overexpressing cells: Acidic, basic, and secondary floxuridine amino acid ester prodrugs Mol. Cancer Ther., April 1, 2005; 4(4): 659 - 667. [Abstract] [Full Text] [PDF] |
||||
|
|